(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.92%.
Oric Pharmaceuticals's earnings in 2026 is -$129,468,000.On average, 18 Wall Street analysts forecast ORIC's earnings for 2026 to be -$146,001,170, with the lowest ORIC earnings forecast at -$173,097,896, and the highest ORIC earnings forecast at -$122,236,339. On average, 14 Wall Street analysts forecast ORIC's earnings for 2027 to be -$160,743,796, with the lowest ORIC earnings forecast at -$184,900,025, and the highest ORIC earnings forecast at -$125,397,623.
In 2028, ORIC is forecast to generate -$173,840,547 in earnings, with the lowest earnings forecast at -$205,553,751 and the highest earnings forecast at -$120,339,568.